Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer
The aim of the study was to evaluate pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors for predicting clinical outcomes after definitive concurrent chemoradiotherapy (CCRT) for cervical cancer. The cases were divided into two groups based...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/10/2199 |
id |
doaj-c5b92df14eb140fab15e8e12d7a081aa |
---|---|
record_format |
Article |
spelling |
doaj-c5b92df14eb140fab15e8e12d7a081aa2021-06-01T00:29:43ZengMDPI AGJournal of Clinical Medicine2077-03832021-05-01102199219910.3390/jcm10102199Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical CancerJeong Won Lee0Ki Ho Seol1Department of Radiation Oncology, Daegu Catholic University School of Medicine, Daegu 42472, KoreaDepartment of Radiation Oncology, Daegu Catholic University School of Medicine, Daegu 42472, KoreaThe aim of the study was to evaluate pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors for predicting clinical outcomes after definitive concurrent chemoradiotherapy (CCRT) for cervical cancer. The cases were divided into two groups based on the values of NLR and PLR: High NLR-PLR (high value in both NLR and PLR) and Low NLR-PLR (low value in either NLR or PLR). The relationships between survival outcomes and the pretreatment NLR-PLR were investigated. Of the 148 patients enrolled in the study, 30 patients died during the median follow-up of 75 months. Based on receiver operating curves, NLR and PLR cut-off values for survival analysis were 2.34 and 148.89. The 10-year overall survival and disease-free survival rates for high NLR-PLR vs. low NLR-PLR were 63.6% vs. 86.2% (<i>p</i> = 0.001) and 63.3% vs. 77.5% (<i>p</i> = 0.026), respectively. Based on a multivariate analysis, independent predictors of overall survival were high NLR-PLR (hazard ratio [HR], 2.435; 95% confidence interval [CI], 1.106–5.361; <i>p</i> = 0.027) and stage (HR 2.659; 95% CI, 1.146–6.613; <i>p</i> = 0.024). Increases in both NLR and PLR are associated with poor survival. Elevation in both NLR and PLR before initiation of CCRT may be a useful biomarker for predicting clinical outcomes.https://www.mdpi.com/2077-0383/10/10/2199cervical cancerchemoradiotherapyneutrophil-to-lymphocyte ratioplatelet-to-lymphocyte ratio |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jeong Won Lee Ki Ho Seol |
spellingShingle |
Jeong Won Lee Ki Ho Seol Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer Journal of Clinical Medicine cervical cancer chemoradiotherapy neutrophil-to-lymphocyte ratio platelet-to-lymphocyte ratio |
author_facet |
Jeong Won Lee Ki Ho Seol |
author_sort |
Jeong Won Lee |
title |
Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer |
title_short |
Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer |
title_full |
Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer |
title_fullStr |
Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer |
title_full_unstemmed |
Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer |
title_sort |
pretreatment neutrophil-to-lymphocyte ratio combined with platelet-to-lymphocyte ratio as a predictor of survival outcomes after definitive concurrent chemoradiotherapy for cervical cancer |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-05-01 |
description |
The aim of the study was to evaluate pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors for predicting clinical outcomes after definitive concurrent chemoradiotherapy (CCRT) for cervical cancer. The cases were divided into two groups based on the values of NLR and PLR: High NLR-PLR (high value in both NLR and PLR) and Low NLR-PLR (low value in either NLR or PLR). The relationships between survival outcomes and the pretreatment NLR-PLR were investigated. Of the 148 patients enrolled in the study, 30 patients died during the median follow-up of 75 months. Based on receiver operating curves, NLR and PLR cut-off values for survival analysis were 2.34 and 148.89. The 10-year overall survival and disease-free survival rates for high NLR-PLR vs. low NLR-PLR were 63.6% vs. 86.2% (<i>p</i> = 0.001) and 63.3% vs. 77.5% (<i>p</i> = 0.026), respectively. Based on a multivariate analysis, independent predictors of overall survival were high NLR-PLR (hazard ratio [HR], 2.435; 95% confidence interval [CI], 1.106–5.361; <i>p</i> = 0.027) and stage (HR 2.659; 95% CI, 1.146–6.613; <i>p</i> = 0.024). Increases in both NLR and PLR are associated with poor survival. Elevation in both NLR and PLR before initiation of CCRT may be a useful biomarker for predicting clinical outcomes. |
topic |
cervical cancer chemoradiotherapy neutrophil-to-lymphocyte ratio platelet-to-lymphocyte ratio |
url |
https://www.mdpi.com/2077-0383/10/10/2199 |
work_keys_str_mv |
AT jeongwonlee pretreatmentneutrophiltolymphocyteratiocombinedwithplatelettolymphocyteratioasapredictorofsurvivaloutcomesafterdefinitiveconcurrentchemoradiotherapyforcervicalcancer AT kihoseol pretreatmentneutrophiltolymphocyteratiocombinedwithplatelettolymphocyteratioasapredictorofsurvivaloutcomesafterdefinitiveconcurrentchemoradiotherapyforcervicalcancer |
_version_ |
1721414776926502912 |